Cargando…

Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients

AIM: To assess the benefit of rituximab with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-DA-EPOCH) regimen as a first-line treatment for patients with diffuse large B-cell lymphoma (DLBCL) presenting with unfavorable or aggressive features, and autologous s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pejša, Vlatko, Prka, Željko, Lucijanić, Marko, Mitrović, Zdravko, Piršić, Mario, Jakšić, Ozren, Ajduković, Radmila, Kušec, Rajko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Croatian Medical Schools 2017
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346894/ https://www.ncbi.nlm.nih.gov/pubmed/28252874 http://dx.doi.org/10.3325/cmj.2017.58.40

Ejemplares similares

Diffuse skin hyperpigmentation in CD30+ lymphoproliferation
por: Prka, Zeljko, et al.
Publicado: (2012)

More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features
por: Lucijanic, Marko, et al.
Publicado: (2021)

P1592: MATCHED CONTROL COMPARISON OF SURVIVAL OF HOSPITALIZED COVID-19 PATIENTS WITH HEMATOLOGICAL MALIGNANCIES, DATA FROM A LARGE TERTIARY CENTER REGISTRY
por: Lucijanic, M., et al.
Publicado: (2022)

PB2127: NO IMPACT OF STATIN USE ON RESPONSE AND SURVIVAL RATES IN NEWLY DIAGNOSED DLBCL PATIENTS TREATED WITH R-DA-EPOCH
por: Sabljic, A., et al.
Publicado: (2022)

Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism
por: Lucijanic, Marko, et al.
Publicado: (2021)

Ruxolitinib withdrawal due to the COVID-19
por: Lucijanic, Marko, et al.
Publicado: (2021)

Comparison of IMPROVE, modified IMPROVE, IMPROVEDD, Padua and CHA2DS2-VASC risk scores for venous and arterial thrombotic events prediction in hospitalized COVID-19 patients
por: Lucijanic, Marko, et al.
Publicado: (2022)

P1229: RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): REAL-LIFE EXPERIENCE ON 225 PATIENTS FROM 4 COUNTRIES
por: Vassilakopoulos, T., et al.
Publicado: (2022)

P1178: THE APPLICABILITY OF PROGNOSTIC MODELS UNDER RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): A COMPARISON WITH R-CHOP
por: Vassilakopoulos, Theodoros, et al.
Publicado: (2023)

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
por: Hasselbalch, Hans, et al.
Publicado: (2022)

Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy?
por: Jessamy, Kegan, et al.
Publicado: (2016)

Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma
por: Dodero, A., et al.
Publicado: (2019)

Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017
por: Jakšić, Branimir, et al.
Publicado: (2018)

P1230: PET/CT IMAGING FOR RESPONSE ASSESSMENT AND TREATMENT GUIDANCE AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH(R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL):THE GREEK EXPERIENCE ON 107 PATIENTS
por: Vassilakopoulos, T., et al.
Publicado: (2022)

Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome
por: Dodero, Anna, et al.
Publicado: (2021)

Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis
por: Lucijanic, Marko, et al.
Publicado: (2023)

PB2220: ATRIAL FIBRILLATION IS FREQUENT IN PATIENTS WITH MYELOFIBROSIS AND MIGHT BE SUB-OPTIMALLY TREATED
por: Lucijanic, Marko, et al.
Publicado: (2023)

Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases
por: Galusic, Davor, et al.
Publicado: (2022)

P1121: POSITRON EMISSION TOMOGRAPHY FOR FINAL RESPONSE ASSESSMENT TO RITUXIMAB-DOSE ADJUSTED EPOCH IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: WHO IS WORTHY TO BE IRRADIATED?
por: Vassilakopoulos, Theodoros, et al.
Publicado: (2023)

PB2194: HIGHER JAK2 ALLELE BURDEN IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS IS ASSOCIATED WITH HIGHER PREVALENCE OF CHRONIC KIDNEY DISEASE AND UNFAVORABLE DYNAMICS OF KIDNEY FUNCTION OVER TIME
por: Lucijanic, Marko, et al.
Publicado: (2023)

Health-related Quality of Life in Croatian General Population and Multiple Myeloma Patients Assessed by the EORTC QLQ-C30 and EORTC QLQ-MY20 Questionnaires
por: Ficko, Sanja Ledinski, et al.
Publicado: (2019)

The cubist epoch
por: Cooper, Douglas, 1911-1984
Publicado: (1970)

The Psychology of Epochs
Publicado: (1852)

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R
por: Lakhotia, Rahul, et al.
Publicado: (2023)

Mengelberg and the symphonic epoch
por: Sollitt, Edna Richolson
Publicado: (1929)

Epochs in the History of Obstetrics
por: Greer, H. L. H.
Publicado: (1935)

The epochs of international law
por: Grewe, Wilhelm G, et al.
Publicado: (2000)

Physicists: epoch and personalities
por: Feinberg, E L, et al.
Publicado: (2011)

The New Epoch in Medicine
por: Ormiston, Robert
Publicado: (1889)

An Epoch in Medical History
Publicado: (1892)

Asymptomatic deep vein thromboses in prolonged hospitalized COVID-19 patients
por: Lucijanic, Marko, et al.
Publicado: (2021)

Reactive macrophage activation syndrome in a patient with parvovirus B19 infection, lymphocytic lichenoid vasculitis, urticaria and angioedema
por: Soldo-Juresa, Dragica, et al.
Publicado: (2010)

Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens
por: Zhang, Fangwen, et al.
Publicado: (2019)

An Important Epoch in Medical Education
Publicado: (1914)

Some Personalities of the Hunterian Epoch
por: Woolf, A. E. Mortimer
Publicado: (1929)

Dental Epochs in the Nineteenth Century
Publicado: (1900)

American epoch : a history of the United States since the 1890's /
por: Link, Arthur S. (Arthur Stanley), 1920-1998
Publicado: (1963)

PB2101: TREATMENT OF AGGRESSIVE B-CELL LYMPHOMA WITH DA-EPOCH-R, A SINGLE CENTRE EXPERIENCE
por: Dimitraki, E.-K., et al.
Publicado: (2022)

Good outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximab
por: Dunleavy, K, et al.
Publicado: (2009)

Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in human immunodeficiency virus-associated, B-cell non-Hodgkin lymphoma
por: Sparano, Joseph A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1qiai6q92vfp7fqfd507a4t40r